Diastolic Murmurs: What You Need to Understand

What It Is

The First Rule of Diastolic Murmurs

Every diastolic murmur is pathological until proven otherwise.

This is not an arbitrary statement. It reflects clinical reality: there are no physiological (innocent) diastolic murmurs in adults under normal conditions. The one exception, the venous hum in children and the mammary soufflé in pregnancy (both covered under innocent murmurs in SDE-F-MURM-003), are not truly cardiac murmurs in the anatomical sense. In the adult with a cardiac diastolic murmur, something structural or hemodynamic is abnormal.

Diastolic murmurs are harder to hear than systolic murmurs for two physiological reasons: diastole is longer than systole (allowing the sound to decay more), and diastolic filling pressures are lower than systolic ejection pressures, generating less turbulent velocity and quieter sounds. Many diastolic murmurs are grade 1 to 2 on the Levine scale and are missed on brief auscultation.

Timing Within Diastole

Diastole spans from S2 (aortic and pulmonic valve closure) to S1 (mitral and tricuspid valve opening and subsequent ventricular contraction). Two periods within diastole are relevant for murmur classification:

Early diastolic murmurs: Begin immediately after S2. Caused by aortic regurgitation (AR) or pulmonic regurgitation (PR). These are decrescendo (highest intensity at S2, falling off as the regurgitant gradient between the aorta/pulmonary artery and the ventricle equalizes during diastole).

Mid-to-late diastolic murmurs: Begin after an interval following S2. Caused by mitral stenosis (MS) or tricuspid stenosis (TS). These begin with the opening snap (for MS) or a similar sound (for TS) and represent turbulent flow across the narrowed atrioventricular valve as the ventricle fills. They may be louder with atrial contraction (presystolic accentuation in sinus rhythm patients with MS).

The Mechanism

Aortic Regurgitation

Aortic regurgitation (AR) occurs when the aortic valve does not close completely in diastole, allowing blood from the high-pressure aorta to flow backward into the left ventricle. The LV receives both the normal mitral inflow from the left atrium and the regurgitant volume from the aorta, producing progressive LV dilation.

The characteristic murmur: high-pitched, blowing, decrescendo, beginning immediately after S2, heard best at the left sternal border (third to fourth intercostal space) with the patient sitting forward in full expiration. Radiation toward the apex in the Gallavardin pattern reflects the Austin Flint murmur (discussed below).

Causes of AR include:

• Bicuspid aortic valve (BAV): The most common cause of isolated AR in patients under 50. BAV is present in 1 to 2 percent of the general population and is inherited in an autosomal dominant pattern with variable penetrance. Associated with aortic root dilation independent of AR severity.
• Calcific degenerative AR: More common in elderly patients with the same risk factors as aortic stenosis. Often coexists with AS.
• Rheumatic heart disease: Worldwide, rheumatic fever remains the most common cause of AR and MS. The 2021 global prevalence of rheumatic heart disease is approximately 40 million cases 5 / Solid .
• Aortic root dilation: Dilatation of the aortic root stretches the annulus and prevents coaptation of the valve leaflets. Causes include hypertension, Marfan syndrome, Loeys-Dietz syndrome, and bicuspid aortic valve-associated aortopathy.
• Endocarditis: Vegetation or leaflet destruction from infective endocarditis can cause acute severe AR, a hemodynamic emergency.
• Aortic dissection: Type A dissection extending to the aortic root can acutely disrupt aortic valve coaptation, producing sudden severe AR.

The natural history of chronic AR divides sharply by severity and LV function. Mild-to-moderate AR with normal LV dimensions can be observed for years without intervention. Severe AR with progressive LV dilation (LVESD > 50 mm, LVEDD > 65 mm) or declining EF (< 55%) requires aortic valve replacement before irreversible myocardial damage occurs 5 / Solid .

Mitral Stenosis

Mitral stenosis (MS) obstructs blood flow from the left atrium to the left ventricle across the mitral valve. Normal mitral valve area is 4 to 6 cm2. Severe MS: < 1.5 cm2.

In the United States, the most common cause is now calcific MS from mitral annular calcification (in elderly women, often with concurrent AS). Globally, rheumatic MS remains the dominant cause 5 / Solid .

The murmur of MS has a specific and memorable pattern. The opening snap (OS) occurs shortly after S2, as the pressure differential between the LA and LV forces the stenotic but still-pliable leaflets open. The S2-OS interval shortens as MS worsens (higher LA pressure brings the OS closer to S2). Following the OS, a low-pitched, rumbling, decrescendo-then-presystolic crescendo murmur at the cardiac apex (the “diastolic rumble”) represents the turbulent flow across the stenotic valve.

The diastolic rumble of MS is one of the most diagnostically specific murmurs in cardiology. It is heard only at the apex, requires the patient to be in the left lateral decubitus position (which brings the LV apex closer to the chest wall), and is enhanced by exercise or any maneuver that increases heart rate (tachycardia shortens diastolic filling time, worsening the gradient). Many clinicians miss it because they do not use the left lateral decubitus position, the bell of the stethoscope (low-pitched sounds require the bell, not the diaphragm), or adequate quiet.

Pulmonic Regurgitation

Pulmonic regurgitation (PR) is the diastolic equivalent of AR for the right side. The Graham Steell murmur is the pulmonic regurgitation murmur heard in patients with significant pulmonary hypertension: a high-pitched, early diastolic decrescendo murmur at the left upper sternal border, indistinguishable from AR by character but louder with inspiration (right-sided accentuation).

Primary PR (from congenital pulmonic valve abnormalities, endocarditis, or carcinoid involvement of the pulmonic valve) produces the same murmur. Secondary PR from pulmonary hypertension is far more common.

Tricuspid Stenosis

Tricuspid stenosis (TS) is rare in developed countries. It is almost exclusively rheumatic in etiology, and when it occurs, it coexists with mitral stenosis in more than 90 percent of cases. The murmur is a low-pitched diastolic rumble at the left lower sternal border, louder with inspiration (right-sided accentuation). It is frequently masked by the louder mitral stenosis murmur that accompanies it.

The Austin Flint Murmur

The Austin Flint murmur is a diastolic rumble at the apex in patients with severe AR. It can be mistaken for mitral stenosis. The mechanism: the regurgitant AR jet from the aorta strikes the anterior mitral leaflet, causing it to vibrate and partially obstruct mitral inflow, producing a low-pitched rumble. The Austin Flint murmur is not associated with an opening snap (no OS because the mitral leaflets are not fused) and does not shorten with maneuvers that lower pulmonary venous pressure (unlike true MS) 5 / Solid .

How We Diagnose / How It Is Used

Auscultation Technique for Diastolic Murmurs

The failure to detect diastolic murmurs is usually a technique failure, not a hearing problem. Key technical requirements:

Quiet environment: Diastolic murmurs are soft. Any ambient noise (television, patient talking, adjacent monitoring equipment) obscures them.

Correct patient position: AR: best heard with patient sitting forward, leaning toward the examiner, in full exhalation. MS: best heard with patient in left lateral decubitus position.

Correct stethoscope component: Low-pitched rumbles (MS, TS, Austin Flint) require the bell (low-frequency mode) with light pressure. High-pitched blowing murmurs (AR, PR, Graham Steell) are heard with the diaphragm.

Breath-holding: The examiner should ask the patient to exhale and hold: this eliminates breath sounds, reduces intrathoracic pressure variation, and reveals the murmur.

The Baumgartner 2009 European Heart Journal systematic review of valve assessment confirmed that trained echocardiographers detect AR and MS clinically with sensitivity above 70 percent and specificity above 80 percent under ideal conditions, but that primary care physicians and medical trainees perform substantially worse under routine clinical conditions 5 / Solid .

Echocardiographic Assessment of Diastolic Murmur Causes

Echocardiography answers three questions for diastolic murmur patients:

1. What is the cause? Morphology of the mitral and aortic valves; rheumatic changes (leaflet thickening, commissure fusion, subvalvular calcification for MS; leaflet prolapse, retraction, or bicuspid anatomy for AR).

2. How severe is it? Quantitative measures: mean gradient and valve area for MS (planimetry or pressure half-time method); regurgitant volume, regurgitant fraction, EROA, and vena contracta width for AR severity staging (mild/moderate/severe/very severe per ASE 2017 guidelines).

3. What has it done to the heart? LV dimensions, LV ejection fraction (which determines intervention timing in AR), left atrial size, and pulmonary artery pressure (raised in MS from chronic LA hypertension).

Transesophageal echocardiography (TEE) is indicated for suspected valve anatomy that requires higher resolution than TTE provides, for pre-procedure planning (balloon mitral valvuloplasty for MS, TEER for MR), and for suspected endocarditis 5 / Solid .

The Intervention Decision for AR: The LV Dimension Thresholds

The 2021 AHA/ACC Valve Guidelines specify surgical AR intervention is indicated (Class I) for:

• Severe AR in symptomatic patients
• Severe AR with LVEF < 55%
• Severe AR with LVESD > 50 mm (or indexed > 25 mm/m2)
• Severe AR with LVEDD > 65 mm (when low surgical risk)

The rationale: AR chronically volume-overloads the LV. The LV adapts initially through dilation. Once EF falls or LV dimensions exceed thresholds, irreversible myocardial damage begins. Intervention before irreversibility preserves ventricular function; intervention after EF declines carries a worse post-operative prognosis 5 / Solid .

The engineer in the opening scene, with LVESD 6.1 cm at age 38, needed regular echocardiographic monitoring every 6 to 12 months with clear established thresholds for when surgery would be recommended.

The Evidence

Natural History Trials in AR and MS

Balloon Mitral Valvuloplasty

For patients with significant MS from rheumatic disease with suitable valve anatomy (non-calcified, non-fused leaflets, no significant MR, no LA thrombus), percutaneous balloon mitral commissurotomy (PBMC, also called percutaneous mitral balloon valvotomy) is effective and preferred over surgical commissurotomy 5 / Solid . The procedure uses a balloon catheter (Inoue balloon) to fracture the fused commissures and increase valve area. MVA improvement from approximately 1.0 cm2 to 1.8 to 2.2 cm2 is typical. Durability: 70 to 75 percent of patients remain free of re-intervention at ten years.

For calcific MS (dominant in the elderly US patient with mitral annular calcification), valve morphology is unsuitable for PBMC; surgical or transcatheter mitral valve replacement is the only option. Transcatheter mitral valve replacement (TMVR) for calcific MS remains technically challenging with high procedural mortality in current series 3 / Early .

The Missed Diastolic Murmur in Primary Care

The primary care literature consistently documents lower rates of diastolic murmur detection compared to cardiologist examination. A key contributor is examination duration: auscultation time in primary care visits has declined substantially in the past two decades. A 2018 study found that cardiologists spent a median of 140 seconds auscultating versus 60 seconds in primary care 4 / Promising .

Electronic stethoscopes with ambient noise cancellation and AI-assisted sound analysis (Eko Core, 3M Littmann Electronic) may improve diastolic murmur detection in primary care by amplifying low-frequency sounds and flagging abnormal patterns. This technology does not replace echocardiography but may reduce the missed-diastolic-murmur problem 4 / Promising .

The Patient Experience

The Patient Who “Always Had a Murmur”

In immigrant communities from countries where rheumatic fever was endemic (Sub-Saharan Africa, South Asia, Latin America, Middle East), adults frequently have known murmurs from childhood or early adulthood that were never systematically followed after emigration. Healthcare systems in the US are not consistently configured to recognize this presentation.

The engineer in the opening scene represents a common archetype: a patient who knew he had a murmur, assumed it was innocent because no one told him otherwise, and was never connected to the regular echocardiographic surveillance that his bicuspid valve and progressive AR required.

The Stop Dying Early Audit is specifically structured to flag this history: prior murmur in an adult from a rheumatic-fever-endemic country, or prior murmur in any adult over 40 with no echocardiographic evaluation in the preceding two to three years.

Symptoms That Patients Attribute to Other Causes

Chronic aortic regurgitation produces symptoms insidiously because the LV adapts for years. Patients often attribute exertional dyspnea to deconditioning, palpitations to anxiety, and reduced exercise capacity to age. By the time they are clearly symptomatic with classic dyspnea on exertion and orthopnea, LV remodeling may already be advanced.

The clinical pearl: in a patient with known AR who reports “just being a little less active than I used to be,” the question is whether this represents true symptom onset (an indication for valve surgery) or gradual adaptation. Stress echocardiography and careful clinical assessment can distinguish these.

Mitral Stenosis and Atrial Fibrillation

One of the most important complications of mitral stenosis is atrial fibrillation. The chronically raised LA pressure from MS leads to LA enlargement, which predisposes to AF. When AF develops in the setting of MS:

1. The atrial kick is lost, which is particularly important in MS because late diastolic transmitral flow from atrial contraction contributes significantly to LV filling in the setting of restricted valve area.
2. The rapid ventricular rate in uncontrolled AF shortens diastolic filling time, dramatically worsening the transmitral gradient and potentially precipitating pulmonary edema.
3. The combination of MS, AF, and LA enlargement creates extremely high stroke risk: the CHA2DS2-VASc score underestimates embolic risk in rheumatic MS with AF 5 / Solid . Anticoagulation in these patients is with warfarin, not novel oral anticoagulants, because NOAC trials excluded significant rheumatic valve disease and ENVISAGE-TAVI and related analyses suggest potential inferiority of NOACs in rheumatic MS 5 / Solid .

Decisions and Trade-Offs

The Timing of Surgery for AR: The LV Dilation Debate

The debate in AR management centers on whether surgery should be performed at the time of severe AR, even before EF decline or LV dilation reaches guideline thresholds, if the surgeon is experienced and the patient is low-risk. The 2021 guidelines created a new Class IIa recommendation allowing consideration of early surgery when LVESD is 45 to 49 mm (below the 50 mm Class I threshold) in low-surgical-risk patients at experienced centers 5 / Solid .

The counterargument: every year of delay before the Class I threshold is a year without surgical risk. The balance depends on the rate of LV dilation, the patient’s age and activity level, and the institutional surgical expertise.

Aortic Root Management in BAV-Associated Aortopathy

For patients with bicuspid aortic valve, AR management cannot be separated from aortic root management. BAV-associated aortopathy carries a risk of aortic dissection independent of the valve hemodynamics. Aortic root replacement thresholds in BAV are 5.0 cm (4.5 cm in patients with additional risk factors) 5 / Solid . The engineer in the opening scene had a 4.3 cm root: surveillance every 6 months.

Anticoagulation Strategy in Mitral Stenosis

For rheumatic MS with AF, warfarin with INR 2.0 to 3.0 is the only anticoagulation strategy with demonstrated efficacy in preventing cardioembolic stroke. Multiple analyses confirm that NOACs are not equivalent to warfarin in this setting. The AFIRE, ARISTOTLE, and ENGAGE AF trials all excluded patients with MS; the specific INVICTUS trial comparing rivaroxaban vs warfarin in rheumatic AF found worse outcomes with rivaroxaban (higher stroke and death rates) 5 / Solid .

For patients with MS who cannot tolerate warfarin monitoring, the clinical path is correcting the valvular disease so that the AF becomes non-rheumatic, at which point NOAC use becomes appropriate.

The SDE Synthesis

Diastolic murmurs are almost invariably pathological and frequently missed. The clinical consequences of missing a diastolic murmur are time-specific: AR found at an LVESD of 40 mm in a 38-year-old gives the cardiologist years to optimize the surveillance and intervention timing. AR found at an LVESD of 62 mm with EF of 38 percent gives the cardiologist a difficult post-operative prognosis conversation.

The SDE program addresses this gap at multiple levels:

In the Champaign-Urbana area, Carle Foundation Hospital’s echocardiography laboratory and structural heart program handles diastolic murmur workup. The University of Illinois Health Chicago campus and Northwestern Medicine Bluhm Cardiovascular Institute provide tertiary valve surgery capabilities. For patients in central Illinois, OSF Heart of Mary Medical Center provides valve surgery access.

The principle is straightforward: a diastolic murmur heard on a stethoscope in 2026 should never become a dilated, dysfunctional LV in 2034 because no one was tracking it. Diastolic murmurs are pathological. They deserve pathological attention.

Rheumatic Heart Disease — A Global Disease With a U.S. Footprint

Rheumatic heart disease is the most common cause of acquired valvular disease worldwide, responsible for approximately 40 million prevalent cases globally and 306,000 deaths per year 5 / Solid 30875-3). In the United States, RHD is often treated as a historical artifact, a disease that belonged to a pre-antibiotic era when streptococcal pharyngitis went untreated, leading to rheumatic fever and progressive valve damage.

That framing is wrong for two reasons.

First, rheumatic heart disease has not disappeared from U.S. practice. It persists in immigrant populations from sub-Saharan Africa, South Asia, Latin America, and the Pacific Islands, where RHD remains endemic. A systematic survey of echocardiographic screening programs in sub-Saharan Africa found RHD prevalence rates of 2 to 3 percent in school-age children in endemic regions, compared to less than 0.1 percent in high-income countries 5 / Solid . Patients from these regions who present to U.S. cardiology clinics in their 30s and 40s with mitral stenosis or combined MR/MS may have decades of undiagnosed disease, often first detected incidentally or during a pregnancy evaluation.

Second, understanding the mechanism of RHD is clinically necessary to managing the sequelae correctly, particularly the valvular disease, atrial fibrillation, and the anticoagulation decisions that follow.

The Pathophysiology of Rheumatic Valvular Damage

Group A Streptococcal (GAS) pharyngitis triggers an autoimmune response in susceptible individuals in which antibodies directed against streptococcal M protein cross-react with cardiac tissue in a process of molecular mimicry. The initial insult is pancarditis, involving all three layers of the heart. Valvular involvement produces an inflammatory process that, over repeated episodes of rheumatic fever, leads to fibrosis, calcification, commissural fusion, and chordal shortening.

The mitral valve is involved in approximately 90 percent of cases, with isolated mitral stenosis in 40 percent, combined MR and MS in 40 percent, and isolated MR in 10 percent 5 / Solid . The aortic valve is involved in approximately 30 percent of cases, almost always in combination with mitral disease. Isolated aortic stenosis from rheumatic disease is uncommon.

The combination of MS and AR produces a clinical picture that requires careful hemodynamic reasoning. The MS restricts forward flow from the left atrium into the LV. The AR adds a volume load to the LV from the aorta. The LV must manage both restricted inflow and excess volume. The echocardiographic and physical examination findings can be misleading if interpreted in isolation: the MS may mask the usual signs of LV dilation from AR, and the increased LV stroke volume from the AR volume overload may increase the gradient across the stenotic mitral valve. These patients need subspecialty structural heart evaluation before any surgical planning.

Mitral Stenosis: The Valve Area Calculus

The normal mitral valve area is 4 to 6 cm². Symptoms from mitral stenosis typically appear when the valve area falls below 2.0 cm² (mild MS) and become more pronounced below 1.5 cm² (moderate MS). Severe MS is defined as a valve area less than or equal to 1.0 cm² 5 / Solid .

The mean gradient across the mitral valve is the other key parameter: a mean gradient above 5 mmHg at rest in moderate MS, and above 10 mmHg in severe MS, broadly categorize disease severity, though gradients are heavily heart rate-dependent. A patient with moderate MS in normal sinus rhythm at a resting heart rate of 60 may have a mean gradient of 6 mmHg at rest. That same patient at a heart rate of 110 during atrial fibrillation may have a mean gradient of 15 mmHg, pulmonary pressures well above 50 mmHg, and acute pulmonary edema.

This heart rate dependence is the central physiological concept in MS management. Slowing the heart rate with a beta-blocker or diltiazem extends diastolic filling time, allowing more blood to cross the stenotic valve per beat, and reduces the mean gradient. Rate control in MS is not simply about managing AF symptoms. It is the primary hemodynamic intervention for decompensated MS. The rhythm strategy decision (rate control versus rhythm control) in MS with AF has additional complexity: rhythm control and restoration of sinus rhythm does not always improve exercise tolerance in advanced MS because the valve area, not the rhythm, is the limiting factor at that stage.

Aortic Regurgitation: Reversing the Volume Overload Before It Becomes Permanent

Aortic regurgitation allows blood to flow backward from the aorta into the LV during diastole. The LV must then eject both its normal forward stroke volume and the regurgitant volume. Over time, it dilates to accommodate this chronic volume overload. The compensated phase of AR can last years or even decades: the LV dilates, maintains high stroke volume through the Frank-Starling mechanism, and the patient has no symptoms.

The clinical trap in AR is the same as in MR: a normal or high-normal LVEF does not mean normal LV function. The high stroke volume in severe AR preserves the apparent ejection fraction. By the time the LVEF begins to decline into the 50s, irreversible myocardial damage may already have occurred.

The LVEF threshold for intervention in severe AR is 55 percent, and LVESD ≥50 mm (or indexed LVESD ≥25 mm/m²) is an independent indication for surgery even in the absence of symptoms 5 / Solid . Unlike AS, where TAVR has largely supplanted surgical AVR in older patients, TAVR for AR is technically more challenging because the regurgitant valve lacks the calcification that anchors a transcatheter device. Most severe AR still requires surgical valve replacement or repair.

Penicillin Prophylaxis and the Secondary Prevention Window

The only intervention that prevents progression of rheumatic heart disease is prevention of recurrent streptococcal infection through secondary prophylaxis with long-acting benzathine penicillin. Monthly intramuscular injections of benzathine penicillin G 1.2 million units reduce the incidence of recurrent rheumatic fever by over 90 percent compared to no prophylaxis 5 / Solid .

Current guidelines recommend secondary prophylaxis for 10 years after the last episode of rheumatic fever, or until age 25 (whichever is longer) in patients without carditis. In patients with confirmed carditis but no persistent valve disease, prophylaxis continues until age 21 or for 10 years, whichever is longer. In patients with established valvular disease, prophylaxis is recommended indefinitely or until age 40 in endemic regions.

In practice, adherence to monthly IM injection programs is poor, particularly in resource-limited settings. Oral penicillin V twice daily is an alternative but has substantially lower adherence and efficacy. This is why echocardiographic screening programs in endemic regions aim to identify subclinical RHD before symptomatic valve disease develops: the window for secondary prophylaxis to prevent progression is widest in early, mild disease.

For the patient already in a U.S. cardiology clinic with established rheumatic valve disease, the prophylaxis conversation is often never had. A 35-year-old Ugandan immigrant with moderate MS diagnosed at Carle Foundation Hospital in Urbana may never have been started on secondary prophylaxis in her home country, may not understand why a monthly injection matters now that she is in the United States, and may never be asked about her childhood history of joint pains and fever that preceded the valve disease by 20 years. The SDE Audit is designed to catch exactly this gap: a structured review that identifies immigrant patients with valve disease, checks for documented prophylaxis history and current status, and initiates appropriate preventive therapy before the next streptococcal exposure triggers another acute rheumatic carditis episode.

Hemodynamic Consequences of Combined Valve Disease and the Surveillance Interval Question

Most cardiology patients do not have one valvular abnormality. They have two or three, each of which interacts with the others in ways that make the individual lesion’s isolated severity thresholds inadequate for clinical decision-making. The patient with moderate MS and moderate MR does not have two moderate lesions that can be safely watched. The combined hemodynamic burden on the left atrium and left ventricle may be severe even though neither lesion individually meets the severe threshold.

The Combined Lesion Problem

There are no large RCTs guiding management of combined valve lesions. The evidence base is observational and registry-based, and the current guidelines acknowledge this gap explicitly. The practical implication: combined valve disease requires individualized assessment by a valve specialist, not algorithmic management by a primary care physician or non-specialist cardiologist using single-lesion thresholds.

When evaluating combined mitral disease (MS + MR), the decision-making algorithm centers on which lesion is the dominant driver of symptoms and LV dysfunction. If the MS is dominant (raised gradient, significant LA enlargement, raised pulmonary pressures), percutaneous mitral balloon commissurotomy or surgical intervention targeting the stenosis takes priority. If MR is dominant (LV dilation, falling LVEF), the MR governs the timing of intervention.

When AR is present alongside AS, the combination is particularly treacherous. Mild AR in a patient with severe AS artificially raises the forward stroke volume across the stenotic aortic valve, producing a higher-than-expected peak velocity and gradient for the degree of effective orifice area reduction. This may lead to overestimation of AS severity by gradient criteria and underestimation by continuity equation area (the low-flow problem in paradoxical low-gradient severe AS). These discordant findings require stress echocardiography, CT aortic valve calcium scoring, and structural heart team discussion rather than isolated guideline application.

Defining the Surveillance Interval

Mild AS: echocardiogram every 3 to 5 years. Moderate AS: every 1 to 2 years. Severe AS (asymptomatic): every 6 to 12 months or more frequently if any progression is detected.

Mild MR: echocardiogram every 3 to 5 years. Moderate primary MR: every 1 to 2 years. Severe primary MR (asymptomatic): every 6 to 12 months.

Mild AR: every 3 to 5 years. Moderate AR: every 1 to 2 years. Severe AR (asymptomatic): every 6 to 12 months with strict attention to LVEF and LV dimensions.

Moderate-to-severe MS: every 1 to 2 years, more frequently if the patient is approaching the threshold for intervention (MVA <1.5 cm²) or is planning pregnancy.

These intervals assume a stable patient with no new symptoms. Any symptom change triggers unscheduled echocardiography. The patient who develops exertional dyspnea between scheduled visits does not wait for the next appointment. She calls and is seen.

The surveillance failure documented in the literature is not the failure to order the first echocardiogram. It is the failure of follow-up: the echo is done, reported, documented, and then the patient is not seen again for 4 years, well past the appropriate surveillance interval for moderate disease. This failure is systematic and well-documented in claims data 5 / Solid . An analysis of Medicare beneficiaries with moderate AS found that only 56 percent of patients had an echocardiogram within guideline-recommended intervals, with younger patients and those in rural areas having the lowest rates of surveillance adherence.

The SDE Cohort program addresses this through structured longitudinal tracking: each enrolled patient has a defined surveillance calendar with automated reminders, and a cardiologist review when the interval is reached. This is not sophisticated technology. It is a scheduled follow-up calendar applied with discipline. The barrier is not the tool. It is the system that makes routine follow-up the exception rather than the default.

When to Act: The Conversation About Elective Versus Urgent Intervention

The most difficult conversation in structural heart disease is the one that happens before the patient is symptomatic. A 72-year-old patient with severe AS and a mean gradient of 48 mmHg, an aortic valve area of 0.82 cm², a preserved LVEF of 64 percent, and no exertional symptoms sits across from you in the clinic.

He mows his own lawn. He walks 4 blocks to church. He does not have chest pain or syncope. His BNP is 180 pg/mL, mildly raised. His CT shows moderate aortic valve calcification and an aortic root suitable for TAVR.

The guideline gives him a Class IIa recommendation for TAVR if his surgical risk is low. The evidence from AVATAR and RECOVERY suggests early intervention reduces major adverse cardiovascular events. But the procedural risk is real: vascular complications occur in 2 to 4 percent, permanent pacemaker implantation in 15 to 20 percent with current-generation devices, and stroke in 1 to 2 percent.

He wants to know: “If I feel fine, why would I have a procedure?”

The answer requires honest translation of probability into meaning. “If we watch and wait, 75 percent of asymptomatic patients with severe AS develop symptoms or die within 5 years without intervention. The 1-year mortality after symptom onset without AVR is 25 percent. Your gradient has been increasing by 5 to 7 mmHg per year over the last two echos. If we plan this now, you go home in 24 hours and are back mowing the lawn in two weeks. If we wait until you are symptomatic and decompensated, the procedural complexity and recovery are greater, and the LV you walk in with is not as healthy as the one you have today.”

That is not a sales pitch. That is clinical medicine with numbers attached. The ability to have that conversation, to translate the echo report into lived-life stakes, is the central function of a patient-facing cardiologist in 2026. No algorithm performs it. No echo report generates it automatically. It requires time, clinical judgment, and a practice model that provides the time.

The Diastolic Murmur in the Emergency Department and the Cardiologist’s Role

Diastolic murmurs discovered in acute settings carry different urgency than those found on routine examination. The two scenarios that constitute cardiac emergencies are acute aortic regurgitation and decompensated mitral stenosis with atrial fibrillation and rapid ventricular response. Both produce diastolic murmurs. Both can kill within hours if not recognized correctly.

Acute Aortic Regurgitation

Acute AR is a hemodynamic emergency with a different physiology than chronic AR. In chronic AR, the LV has time to dilate and accommodate the regurgitant volume. In acute AR, the regurgitant volume enters a normal-sized, non-dilated LV that has no capacity to compensate. The left ventricular end-diastolic pressure rises dramatically. The mitral valve may close prematurely (before atrial systole), producing a distinctive mid-diastolic rumble on echocardiography. Pulmonary edema follows rapidly.

The clinical presentation of acute AR is not the wide pulse pressure of chronic AR. The wide pulse pressure depends on stroke volume amplification through a dilated LV. In acute AR with a normal-sized LV, the pulse pressure is normal or even narrow, the patient is tachycardic and hypotensive, and the murmur is short and soft rather than the long decrescendo of chronic AR. This is why acute AR is frequently missed or underdiagnosed on clinical examination alone: the expected physical findings are absent or misleading 5 / Solid .

The most common causes of acute AR are infective endocarditis (aortic valve or prosthetic valve destruction), aortic dissection (Type A with leaflet involvement), and chest trauma. The treatment is emergency surgical AVR. Medical management alone carries a mortality rate approaching 75 percent within 24 hours for severe acute AR with hemodynamic compromise 5 / Solid . Intravenous nitroprusside reduces afterload and improves forward flow as a bridge to the operating room, but it is a temporizing measure, not definitive therapy.

The emergency physician who hears a soft diastolic murmur in a tachycardic, hypotensive patient with a history of fever and IV drug use should have endocarditis with acute aortic valve destruction as the primary diagnosis until proven otherwise. An echocardiogram must be obtained immediately. Cardiac surgical consultation should follow within minutes of a confirmed finding, not after the cardiology consult is complete.

Decompensated Mitral Stenosis With Rapid AF

The other diastolic emergency occurs when a patient with undiagnosed or known moderate-to-severe MS develops atrial fibrillation with rapid ventricular response. The shortened diastolic filling time at high heart rates means that blood has less time to cross the stenotic mitral valve per beat. Left atrial pressure rises precipitously. Pulmonary edema ensues, sometimes within an hour of the onset of rapid AF.

This is the patient who arrives at HSHS St. John’s Hospital emergency department in Springfield or at Carle Foundation Hospital in Urbana with acute dyspnea, hypoxia, rapid irregular pulse, and a low-grade diastolic rumble at the apex that the emergency physician does not recognize as significant. The ECG shows AF at 130-140 bpm. The chest X-ray shows pulmonary vascular redistribution and Kerley B lines. The BNP is 800 pg/mL.

If the emergency physician initiates IV furosemide and cardiology consultation, the immediate decompensation may be controlled. But the underlying MS has not been treated. The patient has a structural valve problem that will produce the same decompensation at the next AF episode, or progressively with each year of disease progression.

The cardiology consult needs to accomplish three things: confirm the diagnosis echocardiographically, initiate rate control (IV metoprolol or diltiazem), and begin the referral planning for definitive intervention (percutaneous mitral balloon commissurotomy or surgical mitral valve replacement). The acute management does not substitute for the structural plan.

Rate control target in acute decompensated MS is a resting heart rate below 70 bpm and below 90 bpm during light exertion. This is often lower than the AF rate-control targets applied in non-MS AF (below 110 bpm at rest per RACE II), and the distinction matters for prescription 5 / Solid .

Pulmonary Hypertension as the End-Stage of Untreated Diastolic Valve Disease

Both severe MS and severe AR, if left untreated until late stages, produce pulmonary hypertension as a shared endpoint. The mechanisms differ. In MS, the raised left atrial pressure is transmitted backward into the pulmonary venous system, causing passive pulmonary hypertension (pulmonary artery systolic pressure follows LAP). In late-stage severe AR, the dilated, failing LV causes raised left ventricular end-diastolic pressure, raised PCWP, and secondary pulmonary hypertension from the raised venous circuit.

By the time pulmonary hypertension is established, the right ventricle has been exposed to chronically raised pressure and has either compensated (RVH) or begun to fail. An raised right ventricular systolic pressure on echocardiography in the presence of severe left-sided valve disease is not an independent finding. It is a severity marker.

Pulmonary hypertension at the time of mitral valve intervention significantly worsens procedural outcomes and long-term recovery. A mean pulmonary artery pressure above 55 mmHg or a pulmonary vascular resistance above 6 Wood units in severe MS places the patient in a higher-risk category for surgery or percutaneous intervention 5 / Solid . Some of this raised PVR is reversible after successful valve intervention; some is fixed from established pulmonary arterial remodeling. The cardiologist’s goal is to intervene before the PVR crosses the reversible-to-fixed threshold.

This is another argument for early, systematic surveillance. The patient who is identified with moderate MS at age 42 and followed with echocardiograms every 18 months, with prompt intervention when her MVA reaches 1.4 cm² and her pulmonary pressures are still in the reactive range, enters the intervention window with a better hemodynamic profile and a better outcome than the patient who first presents at age 55 with severe MS, longstanding AF, and a mean PA pressure of 50 mmHg.

The diastolic murmur is the door to that conversation. It is not just a sound. It is an early warning with a predictable trajectory. The question is whether the clinical system translates the warning into a plan before the trajectory reaches the irreversible range.